Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Following Another Phase 3 Study Initiation of Viaskin in Peanut Allergy, We Discuss the Data Released To Date.

Ticker(s): DBVT, AIMT

Who's the expert?

Name: Dr Robert Wood - MD

Institution: Johns Hopkins University

  • Professor of Pediatrics and Chief of Pediatric Allergy and Immunology at the Johns Hopkins University School of Medicine, Director of the Johns Hopkins Pediatric Clinical Research  Unit, and Professor of International Health at the Johns Hopkins Bloomberg School of Public Health.  
  • Currently treats over 1,000 patients with peanut allergy.
  • Research focuses on novel treatment approaches for both food allergy and asthma, for which he is currently principal investigator for over 20 ongoing studies.

Interview Questions
Q1.

Please describe your clinical background current treatment of patients with Peanut Allergies.

Added By: joe_mccann
Q2.

Please describe the patient population demographics with Peanut Allergy, their ages, and approximately how many have the  Type 1,  IgE mediated, immediate hypersensitivity reaction, and how many have the delayed and dose dependent response Types 3 and 4?

  • Would Viaskin or AR101 be more suitable in treating one type of allergy than the other?

Added By: joe_mccann
Q3.

Would Viaskin or AR101 work well regardless of the age at which it is introduced to the patient? Are they more effective taken early on, as a child? Does the immune system still adapt to not see peanut protein as a trigger for response in older patients? (AR101 has older patients enrolled in the PALISADE study too, although the majority, 57% of the patients enrolled are between 4-11 years of age)

Added By: joe_mccann
Q4.

Viaskin and AR101 are, at the core, ways to decrease the sensitivity of patients to peanut exposure. In what other ways can a patient achieve that? Are the alternatives more expensive or effective?

Added By: joe_mccann
Q5.

What is the difference between Viaskin, AR101, and basic peanut protein, besides the fact that the drugs have exact measured concentrations, tested dosages, and a good delivery method, through the skin(Viaskin) and orally(AR101). In what way are the main compounds different, and through what mechanism of action do they decrease patient sensitivity to peanut?

Added By: joe_mccann
Q6.

In urgent care settings, what is the first-line of treatment used for treating Peanut Allergy reactions and to stabilize the patient? And what has been the standard of care for long-term desensitization until now?

Added By: joe_mccann
Q7.

In a data presentation released March 2017 from VIPES study in children 6-11 years, DBVT reported that treatment with VP 250 μg showed CRD increase to 1440 mg at month 36, from 44 mg at the start. What is the clinical relevance of going from 44 to 1440 on CRD? How would it translate into the lifestyle changes of the patient?

Added By: joe_mccann
Q8.

In the Phase 3 PALISADE trial of AR101, 62% of the patients were reactors and 38% were non-reactors, up to the 100-mg dose.    Can you discuss the data points on the immune parameters presented, Peanut SPT Peanut-Specific IgE and Ara h 2 IgE.

Added By: joe_mccann
Q9.

Another Viaskin data presentation in March cites Peanut-allergic individuals decreased their risk of an allergic reaction 67- to 5089-fold for all of the diverse products containing peanut, following treatment.  How does this data compare to long-term desensitization treatments you’ve previously used? Is the risk decrease substantial, in your opinion?

Added By: joe_mccann
Q10.

Please discuss how you believe patients and their families will weigh efficacy vs. safety vs. ease of use when considering whether to try new peanut-allergy treatments.

Added By: lerkim
Q11.

Private practitioners of OIT and past OIT trials have used commercially available peanut protein to desensitize patients. Will the availability of this cheap option impact the success of either Viaskin or Aimmune's AR101?

Added By: lerkim
Q12.

With parents, less risky adverse events such as skin rash may have an outsized impact on commercial viability.   Have you had/heard any feedback on skin rash around the Viaskin patch site, the level of discomfort to the child, the ability to maintain consistent dose (i.e. keep the patch on), the willingness to keeping trying in hopes of improving tolerance over time, etc.?  How important a factor is patch site skin rash to the potential success of the product?

Added By: william gerber
Q13.

Have you had/heard feedback on how practical Viaskin patch is?  How compatible is it with the daily routine of active children?  Are there issues keeping the patch in place and viable while swimming, sweating while running around, bathing etc.?

Added By: william gerber
Q14.

How well can the two products be compared due to differences in their trial eligibility criteria? For example: DBV REALISE trial, Ages 4-11, psIgE ≥14 kU/L Aimmune ARTEMIS trial, Ages 4 -17 Years, psIgE ≥ 0.35 kUa/L

Added By: william gerber

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.